New discoveries have been made by researchers at the Luxembourg Center for Systems Biomedicine at the University of Luxembourg.
The origin of this important breakthrough lies in a unique process, research on skin cells from Luxembourg patients. The key to success is the collaboration between the Luxembourg Centre for Systems Biomedicine (LCSB), the Parkinson Research Clinic, the cell bank (Biobank) and the National Research Fund. The LCSB team also worked for seven years with international researchers on this study.
According to Dr. Ibrahim Boussaad of the LCSB, a very rare mutation, at the base of Parkinson’s disease, has been identified by the researchers who also deciphered why this mutation involves the onset of the disease in the patient.
The team of researchers led by Professor Rejko Krüger has indeed found substances in the cells of a patient that would, at least partially, cure Parkinson’s disease. Clinical tests on patients for the production of a drug have not yet been carried out, only lab cultures have been performed so far.
A very important step in the fight against the second most common neurodegenerative disease after Alzheimer’s. Around seven million people around the world are affected by Parkinson’s disease, a number that could double over the next 20 years. The aging of the population is one of the causes of this rapid development, but also pollution of the environment, especially with pesticides which have a serious impact, especially among vulnerable people or who have a hereditary history.